{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:34Z","timestamp":1787009074997,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clonazolam is a designer triazolobenzodiazepine first synthesized in 1971 and is primarily used for its anxiolytic and sedative effects. It became a drug of misuse in 2012 and is known for its high potency and long duration of effect. Previous studies of nitrobenzodiazepines, such as nitrazepam, clonazepam, and flunitrazepam, as well as their metabolites, have demonstrated that bacterial species native to the gastrointestinal tract and active during postmortem (PM) decomposition are capable of affecting positivity and compound-to-metabolite ratios. Further studies have not been performed with clonazolam; however, it possesses the nitro functional group necessary for this biotransformation. To understand whether clonazolam may be similarly affected, PM cases (n\u2009=\u2009288) and driving under the influence of drugs (DUID, n\u2009=\u200954) cases, positive for 8-aminoclonazolam reported by NMS Laboratories from 2020 to 2023, were selected for inclusion in this study. Concentrations of clonazolam and 8-aminoclonazolam were evaluated, and concurrent identification of parent drugs and their metabolites occurred less frequently in PM cases (n\u2009=\u20091, 0.30% of cases) than in DUID cases (n\u2009=\u200921, 38% of cases). The clonazolam concentration in one PM case was 13\u2009ng\/mL. In DUID cases, the median clonazolam concentration was 4.0\u2009ng\/mL and ranged from 2.0 to 10\u2009ng\/mL. 8-Aminoclonazolam had median concentrations of 13 and 19\u2009ng\/mL, with ranges 2.0\u2013580 and 2.8\u201359\u2009ng\/mL for PM and DUID cases, respectively. Due to the ever-changing landscape of the designer benzodiazepine market, in vitro studies of PM microbial biotransformation of clonazolam are unavailable. The data reported herein provide valuable information in the absence of such studies and represent an alternative method of investigating this phenomenon as a potential cause of parent nitrobenzodiazepine to metabolite conversion.<\/jats:p>","DOI":"10.1093\/jat\/bkae069","type":"journal-article","created":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:58:11Z","timestamp":1722736691000},"page":"550-556","source":"Crossref","is-referenced-by-count":6,"title":["Elucidating the potential role of microorganisms in postmortem biotransformation: a comparison of clonazolam and its metabolite in postmortem and DUID cases"],"prefix":"10.1093","volume":"48","author":[{"given":"Brittany K","family":"Casey","sequence":"first","affiliation":[{"name":"NMS Laboratories , Horsham, PA 19044,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-3259","authenticated-orcid":false,"given":"Donna M","family":"Papsun","sequence":"additional","affiliation":[{"name":"NMS Laboratories , Horsham, PA 19044,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mudd","sequence":"additional","affiliation":[{"name":"Texas Department of Public Safety Crime Lab , Austin, TX 78752,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"2024110407421836100_R1","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1093\/jat\/bkac023","article-title":"Reports of adverse events associated with use of novel psychoactive substances, 2017\u20132020: a review","volume":"46","author":"Mohr","year":"2022","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/jat\/bkx031","article-title":"Reports of adverse events associated with use of novel psychoactive substances, 2013\u20132016: a review","volume":"41","author":"Logan","year":"2017","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/jat\/bkad036","article-title":"Increasing prevalence of designer benzodiazepines in impaired driving: a 5-year analysis from 2017 to 2021","volume":"47","author":"Papsun","year":"2023","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/jat\/bkaa043","article-title":"Blood concentrations of designer benzodiazepines: relation to impairment and findings in forensic cases","volume":"44","author":"Heide","year":"2020","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1021\/jm00293a015","article-title":"6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines which have central nervous system depressant activity","volume":"14","author":"Hester","year":"1971","journal-title":"J Med Chem"},{"key":"2024110407421836100_R6","article-title":"World Health Organization 43rd Meeting Expert Committee on Drug Dependence","volume-title":"Critical Review Report: Clonazolam"},{"key":"2024110407421836100_R7","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1093\/jat\/bkac098","article-title":"A fatal case report resulting from the abuse of the designer benzodiazepines clonazolam and flualprazolam in conjunction with dried opium poppy pods","volume":"46","author":"Theofel","year":"2023","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jat\/bky092","article-title":"A liquid-chromatography high-resolution mass spectrometry method for non-FDA approved benzodiazepines","volume":"43","author":"Van Wijk","year":"2019","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R9","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1007\/s00216-016-9439-6","article-title":"Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes","volume":"408","author":"Meyer","year":"2016","journal-title":"Anal Bioanal Chem"},{"key":"2024110407421836100_R10","article-title":"Public Alert: Updated Trend Reporting for the NPS Benzodiazepine Clonazolam Based on Data-Mining for 8-Aminoclonazolam","volume-title":"NPS Discovery","author":"Krotulski","year":"2020"},{"key":"2024110407421836100_R11","article-title":"Q1 2023 NPS Scope Recommendations","volume-title":"NPS Discovery","author":"Krotulski"},{"key":"2024110407421836100_R12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/978-3-030-42917-1_33","volume-title":"Principles of Forensic Toxicology","author":"Levine","year":"2020","edition":"5th"},{"key":"2024110407421836100_R13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/978-3-030-42917-1_34","volume-title":"Principles of Forensic Toxicology","author":"Apple","year":"2020","edition":"5th"},{"key":"2024110407421836100_R14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jat\/27.8.533","article-title":"Mechanisms underlying postmortem redistribution of drugs: a review","volume":"27","author":"Pelissier-Alicot","year":"2003","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R15","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3437","article-title":"Postmortem succession of gut microbial communities in deceased human subjects","volume":"5","author":"DeBruyn","year":"2017","journal-title":"PeerJ"},{"key":"2024110407421836100_R16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082011","article-title":"Biochemistry changes that occur after death: potential markers for determining post-mortem interval","volume":"8","author":"Donaldson","year":"2013","journal-title":"PLoS One"},{"key":"2024110407421836100_R17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040758","article-title":"Comprehensive postmortem analyses of intestinal microbiota changes and bacterial translocation in human flora associated mice","volume":"7","author":"Heimesaat","year":"2012","journal-title":"PLoS One"},{"key":"2024110407421836100_R18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/fsr\/owad025","article-title":"The role of microorganisms in the biotransformation of psychoactive substances and its forensic relevance: a critical interdisciplinary review","volume":"8","author":"de Campos","year":"2023","journal-title":"Forensic Sci Res"},{"key":"2024110407421836100_R19","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.1007\/s00253-018-9414-6","article-title":"Microbial forensics: new breakthroughs and future prospects","volume":"102","author":"Oliveira","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"2024110407421836100_R20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.legalmed.2018.11.002","article-title":"Forensic microbiology applications: a systematic review","volume":"36","author":"Ventura Spagnolo","year":"2019","journal-title":"Leg Med"},{"key":"2024110407421836100_R21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1520\/JFS13791J","article-title":"Postmortem drug metabolism by bacteria","volume":"40","author":"Robertson","year":"1995","journal-title":"J Forensic Sci"},{"key":"2024110407421836100_R22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1520\/JFS16081J","article-title":"Stability of nitrobenzodiazepines in postmortem blood","volume":"43","author":"Robertson","year":"1998","journal-title":"J Forensic Sci"},{"key":"2024110407421836100_R23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/dta.1647","article-title":"Production of human metabolites by gastrointestinal bacteria as a potential source of post-mortem alteration of antemortem drug\/metabolite concentrations","volume":"7","author":"Martindale","year":"2015","journal-title":"Drug Test Anal"},{"key":"2024110407421836100_R24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/jat\/bkab013","article-title":"The development and validation of a novel designer benzodiazepines panel by LC\u2013MS-MS","volume":"45","author":"Mastrovito","year":"2021","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R25","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jat\/bkaa070","article-title":"Flualprazolam blood concentrations in 197 forensic investigation cases","volume":"45","author":"Papsun","year":"2021","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R26","first-page":"1","article-title":"Standard Practices for Method Validation in Forensic Toxicology (1st edn)","volume-title":"ANSI\/ASB Standard 036","year":"2019"},{"key":"2024110407421836100_R27","article-title":"General Requirements for the Competence of Testing and Calibration Laboratories (ISO\/IEC Standard No. 17025:2017)","author":"International Organization for Standardization"},{"key":"2024110407421836100_R28","article-title":"2024 Q1 Scope Recommendations","author":"Krotulski"},{"key":"2024110407421836100_R29","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/jat\/bkac006","article-title":"Long-term stability of benzodiazepines and Z-hypnotic drugs in blood samples stored at varying temperatures","volume":"46","author":"Banaszkiewicz","year":"2023","journal-title":"J Anal Toxicol"},{"key":"2024110407421836100_R30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.fsigen.2018.11.004","article-title":"Estimating the postmortem interval using microbes: knowledge gaps and a path to technology adoption","volume":"38","author":"Metcalf","year":"2019","journal-title":"Forensic Sci Int Genet"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkae069\/58892340\/bkae069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/48\/8\/550\/60385587\/bkae069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/48\/8\/550\/60385587\/bkae069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T02:42:35Z","timestamp":1730688155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/48\/8\/550\/7727262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,5]]},"published-print":{"date-parts":[[2024,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkae069","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,8,5]]}}}